Vischer with Oculis on USD 110 million financing
Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110 million.
Oculis Holding plans to use the net income from the financing to boost the development of a novel neuroprotective clinical candidate, as well as for working capital and general corporate purposes.
The Vischer team
The Vischer lineup working on the matter includes Matthias Staehelin (pictured), Vincent Reardon, Balthasar Müller and Elena Weller (all corporate/M&A) as well as Nadia Tarolli Schmidt and Patrik Fisch (both tax).
